No­vo Nordisk joins No­var­tis, Roche in NL­RP3 are­na, bet­ting $70M cash on NASH, car­diometa­bol­ic us­es

As a drug tar­get, the NL­RP3 in­flam­ma­some has drawn se­ri­ous in­ter­est from Big Phar­ma, in­spir­ing a se­ries of M&A deals from No­var­tis and Roche on top of ven­ture in­vest­ments by oth­ers. Now No­vo Nordisk is jump­ing on the band­wag­on — and the Dan­ish phar­ma gi­ant is tak­ing the tar­get where it knows best.

No­vo Nordisk is get­ting its NL­RP3 in­hibitors from Ven­tus Ther­a­peu­tics, a Ver­sant-backed start­up that set out to make some of the best NL­RP3 drugs out there by in­cor­po­rat­ing new in­sights in­to the struc­ture of the tar­get com­plex.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER